Aliskiren Hemifumarate/Amlodipine Besylate

半延胡索酸阿利吉仑/苯磺酸氨氯地平

Report date: 2026/01/21 14:10:58

Base Information

Drug NameAliskiren Hemifumarate/Amlodipine Besylate
Drug Alias Name苯磺酸氨氯地平/半延胡索酸阿利吉仑Aliskiren Hemifumarate and Amlodipine BesylateAliskiren Fumarate/Amlodipine BesylateAliskiren Hemifumarate/Amlodipine BesilateAliskiren/Amlodipine +[7
ClassificationSmall molecules
Mechanisms of ActionRenin inhibitorsVoltage-gated calcium channel blockers
TargetsVoltage-gated calcium channelRenin
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsEssential HypertensionHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2010/08/26
Country/TerritoryCanadaUnited StatesNetherlands +[22
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active IndicationsHypertension
Inactive IndicationsEssential Hypertension

Other Information

ATC CodeC09XA53
Related LinksKEGG